StudyGraphics #VisualAbstract: Long-term pembrolizumab monotherapy maintains efficacy despite the occurrence of immune-related adverse events in patients with advanced melanoma January 21, 2021 | Teddy Guo Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print Click to read the study in European Journal of Cancer RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract: Protection from SARS-CoV-2 re-infection may be diminished among elderly individuals #VisualAbstract: Tislelizumab plus chemotherapy improves outcomes for advanced squamous non small cell lung cancer over chemotherapy alone #VisualAbstract Rituximab plus high-dose chemotherapy (MegaCHOEP) show similar long-term efficacy to conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma
